Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHST vs CYBN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CYBN Captures Overall Composite Edge (63.8 BUY vs 58.2 HOLD), While BHST Leads 4–2 on Growth & Valuation Pillars

CYBN Overall Winner 6-Pillar Tally: BHST 4 – 2 CYBN Matrix Metrics: BHST 1 – 7 CYBN

As of Nov 20, 2026, Cybin Inc. (CYBN) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.8/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while BHST wins 4–2 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus CYBN at $8.28 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CYBN earns the overall head-to-head edge with a stronger Unified Composite Score (63.8/100 BUY vs. BHST 58.2/100 HOLD) and 1.50β · 54% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile CYBN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHST vs CYBN
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58
CYBN NYSE American Head-to-Head Winner
Cybin Inc.
Pharmaceutical Preparations
$8.28
+1.22% 1D
Market Cap $413.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 54% Vol
Unified Composite Score
63.8 / 100 BUY
Tech 75.0 Fund 66.0 Flow 58.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $7.10 · SMA50: $6.57

6-Pillar Scorecard Institutional Category Breakdown (BHST 4 – 2 CYBN)

Columns: Metric · BHST · CYBN
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.7x N/M
2. Growth & Scale BHST
Revenue Growth (YoY) +3.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $35M N/A
Market Cap $29.9M $413.4M
3. Profitability & Quality CYBN
Gross Margin 59.0% N/A
Operating Margin -18.0% 0.0%
Net Profit Margin -31.2% 0.0%
Return on Equity (ROE) -142.5% -53.0%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$9.4M N/A
Cash Flow Margin -26.6% N/A
Net Cash / Leverage $5.1M Net Cash $5.33 Book/Sh · -53.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CYBN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 169.0% (100th %ile)
Put/Call OI Skew N/A 0.13x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 77.0% of Rev ($27M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHST (1) vs CYBN (7)
Institutional Metric BHST CYBN Criterion Row Edge
Market Capitalization
Scale
$29.9M $413.4M Larger Scale CYBN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+3.8% +0.0% Higher Growth BHST
Operating Margin (TTM)
Profitability
-18.0% 0.0% Higher Margin CYBN
Net Profit Margin
Profitability
-31.2% 0.0% Higher Margin CYBN
Return on Equity (ROE)
Capital Efficiency
-142.5% -53.0% Higher ROE CYBN
52-Week Range Position
Momentum
6% ($1–$7) 59% ($5–$11) Stronger Trend CYBN
Beta / 30D Volatility
Risk Regime
0.25β · 86% Vol 1.50β · 54% Vol Lower Realized Risk CYBN
Unified Institutional Score
Composite Signal
58.2 / 100 (HOLD) 63.8 / 100 (BUY) Higher Composite CYBN
Trailing 12M Revenue (USD)
Operating Scale
$35M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M ($5.1M Net Cash) N/A ($5.33 Book/Sh · -53.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CYBN +67.96 pp
BHST: -17.69% · CYBN: +50.27%
3M Horizon CYBN +57.06 pp
BHST: -17.43% · CYBN: +39.63%
6M Horizon CYBN +57.06 pp
BHST: -17.43% · CYBN: +39.63%
1Y Horizon CYBN +57.06 pp
BHST: -17.43% · CYBN: +39.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs CYBN. Trailing 12-month operating profitability (BHST -18.0% vs CYBN 0.0%) and valuation multiples (BHST N/M vs CYBN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M
CYBN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-53.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CYBN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 169.0%
IV Percentile 100th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CYBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published
CYBN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $413.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHST vs CYBN Key Questions & Quantitative Answers

As of Nov 20, 2026, Cybin Inc. (CYBN) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.8/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while BHST wins 4–2 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus CYBN at $8.28 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CYBN earns the overall head-to-head edge with a stronger Unified Composite Score (63.8/100 BUY vs. BHST 58.2/100 HOLD) and 1.50β · 54% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile CYBN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with CYBN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus N/A for CYBN. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CYBN.

BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas CYBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus CYBN (-53.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, CYBN carries 169.0% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.